The human epidermal growth factor receptor 2 (HER2 or ErbB2) is over-expressed in several cancers, in particular in about 30% of breast tumors [1] and is indicative of a poor prognosis for these patients. This evidence concerns the gene ERBB2 and breast neoplasm.